Dashboard
Manage Tickers

NRXPNRX Pharmaceuticals, Inc.

Nasdaq nrxpharma.com


$ 1.72 $ -0.01 (-0.82 %)    

Tuesday, 20-Aug-2024 09:32:15 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 480.95 $ -0.35 (-0.07 %)
DIA $ 408.56 $ -0.55 (-0.13 %)
SPY $ 559.10 $ -0.06 (-0.01 %)
TLT $ 98.37 $ 0.07 (0.07 %)
GLD $ 233.40 $ -0.32 (-0.14 %)
$ 1.7342
$ 1.72
$ 1.69 x 100
-- x --
$ 1.72 - $ 1.72
$ 1.68 - $ 54.00
120,534
na
18.89M
$ 0.84
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-14-2024 06-30-2024 10-Q
2 05-14-2024 03-31-2024 10-Q
3 03-29-2024 12-31-2023 10-K
4 08-14-2023 06-30-2023 10-Q
5 05-15-2023 03-31-2023 10-Q
6 03-31-2023 12-31-2022 10-K
7 11-14-2022 09-30-2022 10-Q
8 08-15-2022 06-30-2022 10-Q
9 05-16-2022 03-31-2022 10-Q
10 03-31-2022 12-31-2021 10-K
11 11-15-2021 09-30-2021 10-Q
12 08-16-2021 06-30-2021 10-Q
13 05-21-2021 03-31-2021 10-Q
14 04-01-2021 12-31-2020 10-K
15 11-16-2020 09-30-2020 10-Q
16 08-14-2020 06-30-2020 10-Q
17 05-15-2020 03-31-2020 10-Q
18 03-30-2020 12-31-2019 10-K
19 11-14-2019 09-30-2019 10-Q
20 08-14-2019 06-30-2019 10-Q
21 05-15-2019 03-31-2019 10-Q
22 03-15-2019 12-31-2018 10-K
23 11-08-2018 09-30-2018 10-Q
24 08-08-2018 06-30-2018 10-Q
25 05-15-2018 03-31-2018 10-Q
26 03-23-2018 12-31-2017 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

nrx-pharmaceuticals-q2-2024-gaap-eps-075-misses-058-estimate
NRX Pharmaceuticals Q2 2024 GAAP EPS $(0.7...
08/14/2024 20:53:12

NRX Pharmaceuticals (NASDAQ:NRXP) reported quarterly losses of $(0.75) per share which missed the analyst consensus estimate of...

nrx-pharmaceuticals-has-obtained-up-to-approximately-16m-in-convertible-debt-financing-from-an-institutional-investor-to-support-the-2024-new-drug-application-filing-its-two-lead-products-nrx-100-and-nrx-101-and-to-retire-existing-debt-from-streeterville-capital
NRx Pharmaceuticals Has Obtained Up To App...
08/13/2024 11:36:15

hc-wainwright--co-maintains-buy-on-nrx-pharmaceuticals-adjusts-price-target-to-19-1-10-reverse-stock-split
HC Wainwright & Co. Maintains Buy on NRX P...
08/05/2024 19:42:08

HC Wainwright & Co. analyst Vernon Bernardino maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy, adjusts target to $19...

nrx-pharmaceuticals-announce-alignment-with-fda-on-pediatric-study-plan-for-nrx-100-ketamine-remains-on-track-to-file-the-nda-for-nrx-100-in-q4-2024-with-anticipated-pdufa-date-in-q2-2025
NRx Pharmaceuticals Announce Alignment Wit...
07/29/2024 12:46:28

FDA response highlights the importance of addressing suicidal depression in adolescents age 9-17Alignment on initial Pediatric ...

nrx-pharmaceuticals-announced-the-issuance-of-an-order-by-a-utah-arbitrator-denying-the-petition-of-streeterville-capital-to-enjoin-nrxs-planned-spinoff-of-49-of-the-shares-in-hope-therapeutics-to-current-shareholders
NRx Pharmaceuticals Announced The Issuance...
07/29/2024 12:36:34

Petition for a temporary restraining order brought by Streeterville Capital, LLC seeking injunctive relief to prevent spinoff o...

nrx-pharmaceuticals-outlines-potential-paths-to-revenue-and-profitability-in-2025-new-shareholder-update-highlights-potential-2024-revenue-from-hope-therapeutics-branded-clinics-2025-revenue-from-sales-of-nrx-100-iv-ketamine-pending-fda-approval-and-2025-revenue-from-nrx-101-for-suicidal-bipolar-depression-and-akathisia
NRx Pharmaceuticals Outlines Potential Pat...
07/01/2024 12:15:21

nrx-pharmaceuticals-to-proceed-with-two-new-drug-applications-in-2024-nrx-101-returned-to-company-for-filing
NRx Pharmaceuticals To Proceed With Two Ne...
06/28/2024 12:11:46

New Drug Application (NDA) for Accelerated Approval planned for NRX-101 in people with bipolar depression and akathisia in 2024...

nrx-pharmaceuticals-publishes-shareholder-update-letter-update-highlights-potential-implications-of-the-companys-recent-activities-at-the-annual-meeting-of-the-american-society-of-clinical-psychopharmacology
NRx Pharmaceuticals Publishes Shareholder ...
06/10/2024 12:34:55

The June 2024 meeting of the American Society for Clinical Psychopharmacology (ASCP) focused heavily on increasing use of intra...

ascendiant-capital-maintains-buy-on-nrx-pharmaceuticals-lowers-price-target-to-43
Ascendiant Capital Maintains Buy on NRX Ph...
06/07/2024 15:58:38

Ascendiant Capital analyst Edward Woo maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and lowers the price target fro...

nrx-pharmaceuticals-presents-landmark-trial-of-nrx-101-in-suicidal-bipolar-depression-at-the-ascp-annual-meeting-nrx-101-is-the-first-oral-antidepressant-demonstrated-to-reduce-suicidality-in-bipolar-depression
NRx Pharmaceuticals Presents Landmark Tria...
05/28/2024 12:47:34

Poster presentation of "A Randomized, Double-Blind Controlled Comparison of NRX-101 (D-cycloserine/lurasidone) to Lurasidon...

12-health-care-stocks-moving-in-thursdays-intraday-session
12 Health Care Stocks Moving In Thursday's...
05/16/2024 16:31:11

nrx-pharmaceuticals-q1-eps-074-misses-037-estimate
NRX Pharmaceuticals Q1 EPS $(0.74) Misses ...
05/14/2024 20:37:04

NRX Pharmaceuticals (NASDAQ:NRXP) reported quarterly losses of $(0.74) per share which missed the analyst consensus estimate of...

12-health-care-stocks-moving-in-mondays-intraday-session
12 Health Care Stocks Moving In Monday's I...
05/06/2024 16:31:16

nrx-pharmaceuticals-announces-final-clinical-trial-results-believes-demonstration-of-reduced-akathisia-in-setting-of-comparable-antidepressant-efficacy-constitutes-basis-for-accelerated-fda-approval-of-nrx-101
NRx Pharmaceuticals Announces Final Clinic...
05/06/2024 12:33:56

12-health-care-stocks-moving-in-wednesdays-pre-market-session
12 Health Care Stocks Moving In Wednesday'...
05/01/2024 12:06:50

12-health-care-stocks-moving-in-tuesdays-after-market-session
12 Health Care Stocks Moving In Tuesday's ...
04/30/2024 20:31:25

gold-down-over-2-3m-profit-beats-expectations
Gold Down Over 2%; 3M Profit Beats Expecta...
04/30/2024 18:37:24

why-he-equipment-services-shares-are-trading-lower-by-around-18-here-are-other-stocks-moving-in-tuesdays-mid-day-session
Why H&E Equipment Services Shares Are Trad...
04/30/2024 17:24:09

12-health-care-stocks-moving-in-tuesdays-intraday-session
12 Health Care Stocks Moving In Tuesday's ...
04/30/2024 16:31:18

why-is-nrx-pharmaceuticals-stock-falling-after-data-from-suicidal-bipolar-depression-study
Why Is NRx Pharmaceuticals Stock Falling A...
04/30/2024 15:46:55

NRX Pharmaceuticals announces Phase 2b/3 trial findings of NRX-101 vs. Lurasidone for Suicidal Bipolar Depression.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION